Human factors validation of a pegcetacoplan on-body injector demonstrates ease of use by adolescents with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (ASN 2025 C3G) - Apellis Medical Hub

Home / Congress Presentations / C3G and Primary IC-MPGN / ASN 2025

Human factors validation of a pegcetacoplan on-body injector demonstrates ease of use by adolescents with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis

Share Via Email

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.